A detailed history of Adar1 Capital Management, LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 911,182 shares of CYTK stock, worth $45.8 Million. This represents 7.82% of its overall portfolio holdings.

Number of Shares
911,182
Previous 853,862 6.71%
Holding current value
$45.8 Million
Previous $46.3 Billion 3.99%
% of portfolio
7.82%
Previous 8.73%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$51.22 - $60.16 $2.94 Million - $3.45 Million
57,320 Added 6.71%
911,182 $48.1 Billion
Q2 2024

Aug 13, 2024

BUY
$47.86 - $75.05 $25.6 Million - $40.1 Million
534,352 Added 167.24%
853,862 $46.3 Billion
Q1 2024

May 15, 2024

BUY
$63.75 - $108.06 $14.5 Million - $24.6 Million
227,428 Added 246.98%
319,510 $22.4 Billion
Q4 2023

Feb 14, 2024

BUY
$26.88 - $83.49 $2.48 Million - $7.69 Million
92,082 New
92,082 $7.69 Billion

Others Institutions Holding CYTK

About CYTOKINETICS INC


  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.73B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Adar1 Capital Management, LLC Portfolio

Follow Adar1 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adar1 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adar1 Capital Management, LLC with notifications on news.